Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

As the market rallies, Raymond James, Tapestry and U.S. Bancorp lead a slew of stocks to watch in or near buy range.

Glaukos (GKOS) just reported record second quarter sales and raised its 2026 net sales guidance to a range of $680 million to $700 million, putting fresh attention on the stock. See our latest analysis for Glaukos. The raised 2026 guidance and record quarter have come alongside sharp share price momentum, with Glaukos posting a 20.6% 1 month share price return and a 52.2% year to date share price return, contributing to a 95.8% 1 year total shareholder return. If this kind of move has your...

In late July 2026, Glaukos Corporation reported record second-quarter results, with net sales rising to US$185.61 million and a narrower quarterly loss, and raised its 2026 net sales guidance to US$680 million–US$700 million from US$620 million–US$635 million. Alongside the guidance increase, Glaukos completed enrollment in its pivotal U.S. PRESERFLO MicroShunt study, underscoring how expanding clinical programs and strong uptake of products like iDose TR and Epioxa are shaping expectations...

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

Moby summary of Glaukos Corporation's Q2 2026 earnings call

Glaukos Corp (GKOS) posts a 50% revenue jump to $185.6 million, driven by iDose TR and Epioxa, while navigating LCD challenges and a Q3 corneal health transition.

Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management’s exp

The stock market sold off as oil prices surged on Trump's Iran threats. Microsoft, Meta and Fortinet were key earnings movers late.

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Glaukos (GKOS) delivered earnings and revenue surprises of +50.00% and +24.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.

Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.